# SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer

Source: https://onco.cc/trials/nct07837362/  
OnCo record `nct07837362` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of capecitabine and fOLFOX (5-FU, leucovorin, oxaliplatin) in colorectal cancer, run by Fudan University, not yet recruiting.

## Summary

SCRT Combined With CAPOX and PD-1/CTLA4 Antibody for Early-stage Low Rectal Cancer is a phase 2, interventional study registered as NCT07837362 by Fudan University, with a registry enrolment figure of 34 participants, started 2026-09-01 and due to reach its primary completion in 2027-12-31. Interventions recorded: Shor-course radiotherapy; PD-1/CTLA4 Antibody; Capecitabine; Oxaliplatin. Conditions listed: Early Low Rectal Cancer. Primary outcome: complete response (CR) rate. Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07837362
- Phase: 2
- Setting: The Combination of PD-1/CTLA4 Antibody and Neoadjuvant Short-course Radiotherapy in Early-stage Low Rectal Cancer
- Sponsor: Fudan University
- Enrolled: 34

## Sources

- ClinicalTrials.gov NCT07837362: https://clinicaltrials.gov/study/NCT07837362

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07837362.json